A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

BACKGROUND: Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. METHODS: Study design: COMBIVAS is a randomised, double-blind, placebo-controlled trial...

Descripción completa

Detalles Bibliográficos
Autores principales: McClure, Mark E., Gopaluni, Seerapani, Wason, James, Henderson, Robert B., Van Maurik, Andre, Savage, Caroline C.O., Pusey, Charles D., Salama, Alan D., Lyons, Paul A., Lee, Jacinta, Mynard, Kim, Jayne, David R., Jones, Rachel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007661/
https://www.ncbi.nlm.nih.gov/pubmed/36906660
http://dx.doi.org/10.1186/s13063-023-07218-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007661/
https://www.ncbi.nlm.nih.gov/pubmed/36906660
http://dx.doi.org/10.1186/s13063-023-07218-y

Ejemplares similares